NSCLC patients who were included in Guangzhou medical insurance were analyzed. The efficacy and adverse reactions were evaluated. All the patients were followed-up regularly and the cost of the treatment was recorded. Results The median progression free survival (PFS) of all patients was 15.0 months. 49 patients received gefintib and 17 patients had erlotinib. The PFS for the two groups of patients was 17.5 month and 13 months, respectively (P=0.459). 31 (62.3%) patients had rash in gefitinib group, 16 (94.1%) in erlotinib group. Cost-effectiveness ratio (CER) in gefitinib group was 3,027 RMB per month, while 6,800 RMB in erlotinib group. The incremental cost-effectiveness ratio (ICEA) of erlotinib was 2.25 times of gefitinib.
free survival, PFS）为4个-6个月，中位生存期（overall survival, OS）仅为10个-12个月 [5] www.lungca.org Guangzhou medical insurance fixed payment procedure was started from February 2010, the patients who enrolled before were excluded from the analysis of cost-effectiveness with medical insurance.
* Guangzhou medical insurance can cover 15,000 RMB at most for patients per month.
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